Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults
Wolf‐­Henning Boehncke, Nicolò Costantino Brembilla, Michael J. Nissen
Expert Review of Clinical Immunology (2020) Vol. 17, Iss. 1, pp. 5-13
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Laurent Peyrin–Biroulet, Jessica R. Allegretti, David T. Rubin, et al.
Gastroenterology (2023) Vol. 165, Iss. 6, pp. 1443-1457
Open Access | Times Cited: 48
Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies
Nicolò Costantino Brembilla, Wolf‐­Henning Boehncke
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 44
Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease
Luis Antonio Díaz, Sheldon Morris, Shravan Dave, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 2
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
Philip J. Mease, Iain B. McInnes, Lai‐Shan Tam, et al.
Lara D. Veeken (2021) Vol. 60, Iss. 5, pp. 2109-2121
Open Access | Times Cited: 56
Phage Display Technology as a Powerful Platform for Antibody Drug Discovery
Kazuya Nagano, Yasuo Tsutsumi
Viruses (2021) Vol. 13, Iss. 2, pp. 178-178
Open Access | Times Cited: 52
Psoriasis and Psoriatic Arthritis—Associated Genes, Cytokines, and Human Leukocyte Antigens
Marek Zalesak, Ľuboš Danišovič, Stefan Harsanyi
Medicina (2024) Vol. 60, Iss. 5, pp. 815-815
Open Access | Times Cited: 5
The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics
Ana G. Abril, Mónica Carrera, Vicente Notario, et al.
Antibiotics (2022) Vol. 11, Iss. 5, pp. 653-653
Open Access | Times Cited: 22
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Christopher T. Ritchlin, Philip J. Mease, Wolf‐­Henning Boehncke, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002195-e002195
Open Access | Times Cited: 21
Landscape of new drugs and targets in inflammatory bowel disease
Sophie Vieujean, Ferdinando D’Amico, Patrick Netter, et al.
United European Gastroenterology Journal (2022) Vol. 10, Iss. 10, pp. 1129-1166
Open Access | Times Cited: 21
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
Yiying Xue, Husheng Mei, Yisa Chen, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 11
Case reports/Case report
AA VV AA VV
Dental Cadmos (2024) Vol. 01, Iss. 01, pp. 24-24
Open Access | Times Cited: 4
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
Christopher T. Ritchlin, Atul Deodhar, Wolf‐­Henning Boehncke, et al.
ACR Open Rheumatology (2023) Vol. 5, Iss. 3, pp. 149-164
Open Access | Times Cited: 10
Pathogenesis-oriented therapy of psoriasis using biologics
Wolf‐­Henning Boehncke, Nicolò Costantino Brembilla
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1463-1473
Closed Access | Times Cited: 13
A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode
Dongping Zhao, Liqin Liu, Xinlin Liu, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Alexis Ogdie, John Tesser, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 6, pp. 1479-1501
Open Access | Times Cited: 8
Guselkumab: a new etiological factor of Medication Related Osteonecrosis of the Jaw (MRONJ)? A case report
Monica Marotta, Paolo Boffano, Errico Prota, et al.
Journal of Stomatology Oral and Maxillofacial Surgery (2024) Vol. 125, Iss. 5, pp. 101985-101985
Closed Access | Times Cited: 2
Novel Therapies for Patients With Inflammatory Bowel Disease.
Priscila Santiago, Manuel B. Braga Neto, Edward V. Loftus
PubMed (2022) Vol. 18, Iss. 8, pp. 453-465
Closed Access | Times Cited: 9
Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates
Khalid A. Alnaqbi, Suad Hannawi, Rajaie Namas, et al.
International Journal of Rheumatic Diseases (2022) Vol. 25, Iss. 10, pp. 1107-1122
Open Access | Times Cited: 6
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Alexis Ogdie, Soumya D. Chakravarty, et al.
Drugs - Real World Outcomes (2022) Vol. 9, Iss. 4, pp. 617-628
Open Access | Times Cited: 6
Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712
Eric C. Breinlinger, Stacy Van Epps, Michael Friedman, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14335-14356
Closed Access | Times Cited: 3
Endometriosis through an immunological lens: a pathophysiology based in immune dysregulation
Alison McCallion, Danielle J Sisnett, Katherine B Zutautas, et al.
Exploration of Immunology (2022), pp. 454-483
Open Access | Times Cited: 5
Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis
Dario Buononato, Gaetano Licata, Alessio Gambardella, et al.
Dermatology Practical & Conceptual (2022), pp. e2022049-e2022049
Open Access | Times Cited: 4
Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The SPRING study
L. Puig, E. Daudén, Manuel Cuervas-Mons, et al.
Journal of the European Academy of Dermatology and Venereology (2023)
Closed Access | Times Cited: 2
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, et al.
Advances in Therapy (2022) Vol. 39, Iss. 10, pp. 4613-4631
Closed Access | Times Cited: 3
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study
Ricardo Ruíz‐Villaverde, Lourdes Rodriguez‐Fernandez‐Freire, José Carlos Armario Hita, et al.
F1000Research (2022) Vol. 11, pp. 1178-1178
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top